睿智医药(300149) - 2022 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2022 was CNY 345,340,861.01, a decrease of 17.00% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2022 reached CNY 66,807,165.81, an increase of 589.07% year-on-year[5] - The net profit excluding non-recurring gains and losses for Q3 2022 was CNY 62,564,174.47, up 1,497.54% from the previous year[5] - Total operating revenue for the current period is ¥1,032,237,378.52, a decrease of 18.14% compared to ¥1,261,483,497.11 in the previous period[22] - Net profit for the current period is ¥1,023,227,946.22, significantly up from ¥14,696,541.00 in the previous period, indicating a substantial increase[24] - Earnings per share (EPS) for the current period is ¥2.0542, compared to ¥0.0298 in the previous period, showing a remarkable growth[25] Assets and Liabilities - Total assets as of September 30, 2022, were CNY 4,704,447,163.36, reflecting an increase of 11.54% from the end of the previous year[5] - As of September 30, 2022, the total current assets amounted to ¥1,604,725,211.85, a significant increase from ¥687,744,820.18 at the beginning of the year, reflecting a growth of approximately 133%[19] - The total liabilities decreased to ¥1,667,990,232.50 from ¥2,228,514,640.12, a reduction of approximately 25%[20] - The company's long-term investments increased to ¥200,833,672.98 from ¥175,963,635.87, reflecting a growth of about 14.1%[20] - The total non-current assets were reported at ¥3,099,721,951.51, down from ¥3,529,846,706.50, indicating a decrease of about 12.2%[20] Cash Flow - Cash flow from operating activities for the year-to-date was negative CNY 64,380,653.93, a decrease of 124.56% compared to the previous year[15] - The cash inflow from financing activities was 226,000,000.00 CNY, compared to 433,558,281.11 CNY in the previous year[27] - The net cash flow from investment activities was 1,295,554,689.49 CNY, compared to a negative cash flow of -249,156,566.84 CNY in the previous year[27] - Cash and cash equivalents at the end of the period totaled 703,629,140.59 CNY, up from 305,332,809.78 CNY year-over-year[27] - The net increase in cash and cash equivalents for the period was 550,636,092.78 CNY, compared to 59,498,825.87 CNY in the previous year[27] Investment and Other Income - Investment income for the year-to-date was CNY 1,359,661,265.46, a significant increase of 27,953.66% year-on-year, primarily due to the disposal of subsidiaries[12] - The company reported an investment income of ¥1,359,661,265.46, a significant increase from ¥4,846,645.06 in the previous period[22] - Other comprehensive income after tax for the current period is ¥29,215,107.02, compared to a loss of ¥672,079.71 in the previous period[24] Equity and Return Metrics - The weighted average return on equity for Q3 2022 was 2.25%, an increase of 1.85 percentage points year-on-year[5] - The total equity attributable to shareholders increased to CNY 3,011,988,517.40, up 53.33% from the end of the previous year[5] - The company reported a total equity of ¥499,776,892.00, unchanged from the previous period[20] Research and Development - Research and development expenses decreased to ¥80,277,254.61 from ¥90,982,840.49, a reduction of 11.88%[22] Miscellaneous - The company has not disclosed any new product developments or market expansion strategies in the current report[18] - The company did not undergo an audit for the third quarter report[28] - The report was released by the board of directors on October 27, 2022[29]